David W. Litchfield

Western University — Canada

Biochemistry, Genetics and Molecular Biology · Life Sciences

65h-index12.2kcitations205works2.82yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Protein Kinase Regulation and GTPase Signaling(64), Cell death mechanisms and regulation(24), Cancer-related Molecular Pathways(24), Signaling Pathways in Disease(20), PI3K/AKT/mTOR signaling in cancer(13)

Publications205 total

Development of a potent and selective chemical probe for the pleiotropic kinase CK2
UNC Libraries·2025Open Access
Covalent Inhibition of the Peptidyl‐Prolyl Isomerase Pin1 by Sulfopin Results in a Broad Impact on the Phosphoproteome of Human Osteosarcoma U2‐OS Cells
PROTEOMICS·2025Open Access
Protein kinase CK2 sustains de novo fatty acid synthesis by regulating the expression of SCD-1 in human renal cancer cells
Cancer Cell International·2024· 4 citedOpen Access
Body weight control via protein kinase CK2: diet-induced obesity counteracted by pharmacological targeting
Metabolism·2024· 5 citedOpen Access
Novel Pannexin 1 isoform is increased in cancer
2024Open Access
Casein kinase 2 phosphorylates and induces the SALL2 tumor suppressor degradation in colon cancer cells
Cell Death and Disease·2024· 8 citedOpen Access
Chemical proteomics reveals the target landscape of 1,000 kinase inhibitors
Nature Chemical Biology·2023· 69 citedOpen Access
Involvement of the AKT Pathway in Resistance to Erlotinib and Cabozantinib in Triple-Negative Breast Cancer Cell Lines
Biomedicines·2023· 6 citedOpen Access
Towards the CSNK2 phosphoproteome – With lessons from the COVID-19 pandemic to revealing the secrets of CSNK2 and its promise as a therapeutic target
Biochimica et Biophysica Acta (BBA) - General Subjects·2023· 2 cited
Comparison of CX-4945 and SGC-CK2-1 as inhibitors of CSNK2 using quantitative phosphoproteomics: Triple SILAC in combination with inhibitor-resistant CSNK2
Current Research in Chemical Biology·2023· 11 citedOpen Access
Chemical Genetic Validation of CSNK2 Substrates Using an Inhibitor-Resistant Mutant in Combination with Triple SILAC Quantitative Phosphoproteomics
Frontiers in Molecular Biosciences·2022· 11 citedOpen Access
CSNK2 in cancer: pathophysiology and translational applications
British Journal of Cancer·2021· 46 citedOpen Access
CK2 Regulation: Perspectives in 2021
Biomedicines·2021· 81 citedOpen Access
An Unbiased Evaluation of CK2 Inhibitors by Chemoproteomics: Characterization of Inhibitor Effects on CK2 and Identification of Novel Inhibitor Targets
UNC Libraries·2021· 6 citedOpen Access
Development of a potent and selective chemical probe for the pleiotropic kinase CK2
Cell chemical biology·2021· 107 citedOpen Access
Pannexin 1 mutation found in melanoma tumor reduces phosphorylation, glycosylation, and trafficking of the channel-forming protein
Molecular Biology of the Cell·2021· 29 citedOpen Access
Dual Modes of Interaction between XRCC4 and Polynucleotide Kinase/Phosphatase: IMPLICATIONS FOR NONHOMOLOGOUS END JOINING
UNC Libraries·2020· 2 citedOpen Access
An Unbiased Proteomic Screen Reveals Caspase Cleavage Is Positively and Negatively Regulated by Substrate Phosphorylation
UNC Libraries·2020Open Access
CSNK2 in cancer: Pathophysiology and translational applications.
Journal of Clinical Oncology·2020· 3 cited
BIRC6 mediates imatinib resistance independently of Mcl-1
UNC Libraries·2020Open Access
page 1 of 11Next →

Frequent Co-authors

Bernhard Lüscher(8), James S. Duncan(6), E G Krebs(5), Fred J. Lozeman(5), Laszlo Gyenis(5), Greg Vilk(4), Robert N. Eisenman(3), H. O. Kleine(3), C. Piening(3), Kevin C. Graham(3), Denis G. Bosc(3), Ronald B. Saulnier(3), Edwin G. Krebs(2), Brian H. Shilton(2), Timothy Haystead(2), Koji Takio(2), Kenneth A. Walsh(2), R. Daniel Gietz(2), Christopher J. Brandl(2), Kelly Duncan(2)